Elizabeth Bilotti

1.5k total citations · 1 hit paper
29 papers, 832 citations indexed

About

Elizabeth Bilotti is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Elizabeth Bilotti has authored 29 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 14 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Elizabeth Bilotti's work include Multiple Myeloma Research and Treatments (23 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Protein Degradation and Inhibitors (10 papers). Elizabeth Bilotti is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Protein Degradation and Inhibitors (10 papers). Elizabeth Bilotti collaborates with scholars based in United States, Ukraine and Spain. Elizabeth Bilotti's co-authors include Danelle F. James, Weiqiang Zhao, Kristie A. Blum, Jeffrey A. Jones, Jan A. Burger, Nyla A. Heerema, Amy J. Johnson, Cathy Zhou, Steven Coutré and Susan O’Brien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Elizabeth Bilotti

29 papers receiving 815 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →

Peers

Elizabeth Bilotti

GENET

PFM

HEMAT

IMMUN

Luciano Levato Italy

Andrzej Pluta Poland

Sandra Dai United States

Emily Hsu United States

Jennifer Orchard United Kingdom

Zafiris Kartasis Greece

Nilima Parry‐Jones United Kingdom

J.J. Sotto France

Hai‐Rong Qiu China

M Levade France

Luciano Levato Italy

Elizabeth Bilotti

440 ×0.8

GENET

257 ×0.6

PFM

268 ×0.7

HEMAT

82 ×0.3

189 ×0.9

IMMUN

Citations per year, relative to Elizabeth Bilotti Elizabeth Bilotti (= 1×) peers Luciano Levato

Countries citing papers authored by Elizabeth Bilotti

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Bilotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Bilotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Bilotti more than expected).

Fields of papers citing papers by Elizabeth Bilotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Bilotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Bilotti. The network helps show where Elizabeth Bilotti may publish in the future.

Co-authorship network of co-authors of Elizabeth Bilotti

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Bilotti. A scholar is included among the top collaborators of Elizabeth Bilotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Bilotti. Elizabeth Bilotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Byrd, John C., Dariusz Woszczyk, Árpád Illés, et al.. (2023). A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood. 142(Supplement 1). 4634–4634. 2 indexed citations

Buske, Christian, Shalal Sadullah, Efstathios Kastritis, et al.. (2018). Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. The Lancet Haematology. 5(7). e299–e309. 28 indexed citations

Richardson, Paul G., William Bensinger, Carol Ann Huff, et al.. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology. 180(6). 821–830. 30 indexed citations

Chari, Ajai, Sarah M. Larson, Beata Holkova, et al.. (2018). Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 59(11). 2588–2594. 20 indexed citations

Coutré, Steven, Richard R. Furman, Ian W. Flinn, et al.. (2017). Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research. 23(5). 1149–1155. 47 indexed citations

Bilotti, Elizabeth, David H. Vesole, Laura McBride, et al.. (2016). Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 16(10). 558–562. 4 indexed citations

Chari, Ajai, Saurabh Chhabra, Saad Z. Usmani, et al.. (2015). Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood. 126(23). 377–377. 6 indexed citations

Sanchez, Larysa, Yucai Wang, Laura McBride, et al.. (2015). Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial. Blood. 126(23). 4264–4264. 1 indexed citations

O’Brien, Susan, Steven Coutré, Richard R. Furman, et al.. (2015). Durable Responses Including Complete Responses in CLL Following Long Term Treatment With Single-agent Ibrutinib 420 mg. Clinical Lymphoma Myeloma & Leukemia. 15. S23–S23. 1 indexed citations

10.

Chhabra, Saurabh, Saad Z. Usmani, Sarah M. Larson, et al.. (2015). The Bruton's tyrosine kinase inhibitor ibrutinib in combination with carfilzomib in patients with relapsed or relapsed and refractory multiple myeloma: initial results from a multicenter phase 1/2b study. Clinical Lymphoma Myeloma & Leukemia. 15. e275–e276. 1 indexed citations

11.

Richardson, Paul G., Jack W. Singer, Carol Ann Huff, et al.. (2015). Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial. Clinical Lymphoma Myeloma & Leukemia. 15. e80–e81. 2 indexed citations

12.

Vij, Ravi, Carol Ann Huff, William Bensinger, et al.. (2014). Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. Blood. 124(21). 31–31. 9 indexed citations

13.

Bilotti, Elizabeth. (2013). Carfilzomib: A Next-Generation Proteasome Inhibitor for Multiple Myeloma Treatment. Clinical journal of oncology nursing. 17(2). E35–E44. 4 indexed citations

14.

Siegel, David S., Laura McBride, Elizabeth Bilotti, et al.. (2012). Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 12(3). 186–190. 2 indexed citations

15.

Bilotti, Elizabeth, et al.. (2011). Routine Health Maintenance in Patients Living With Multiple Myeloma. Clinical journal of oncology nursing. 15(0). 25–40. 11 indexed citations

16.

Bilotti, Elizabeth, et al.. (2011). Survivorship Care Guidelines for Patients Living With Multiple Myeloma. Clinical journal of oncology nursing. 15(0). 5–8. 21 indexed citations

17.

Hoeven, Karen H. van, Laura McBride, Elizabeth Bilotti, et al.. (2011). The Anion Gap and Routine Serum Protein Measurements in Monoclonal Gammopathies. Clinical Journal of the American Society of Nephrology. 6(12). 2814–2821. 9 indexed citations

18.

Siegel, David A., Elizabeth Bilotti, & Karen H. van Hoeven. (2009). Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies. Laboratory Medicine. 40(6). 363–366. 17 indexed citations

19.

Bilotti, Elizabeth, Kathleen Colson, Kathleen M. Curran, et al.. (2008). Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 9–12. 13 indexed citations

20.

Faiman, Beth, et al.. (2008). Steroid-Associated Side Effects in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 53–62. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact